PCCA基因变异rs16957301是接受ICI治疗患者特有的急性肾损伤风险基因型:来自All of Us队列的真实世界证据
本研究利用All of Us队列,从14个免疫相关不良事件候选变异中筛选ICI相关急性肾损伤(ICI-AKI)的遗传易感位点。ICI治疗队列(n=414)一年AKI发生率为23.2%,显著高于一般队列(6.5%,n=213,282)。PCCA基因rs16957301在自报白人和祖先估计欧洲人中与ICI-AKI风险显著相关,该变异在一般队列中未见显著AKI风险。
要点
- ICI治疗队列一年AKI发生率为23.2%,显著高于一般队列的6.5%。
- PCCA rs16957301在自报白人(OR=2.53,Bonferroni校正P=0.047)和祖先估计欧洲人(OR=2.56,Bonferroni校正P=0.044)中与ICI-AKI风险相关。
- 携带rs16957301风险基因型(TC/CC)的自报白人AKI发生更早(3.6个月 vs 参考基因型TT 7.0个月,log-rank P=0.04)。
核心结论
- 研究提示PCCA基因rs16957301可能作为高加索人群ICI-AKI的风险标志物。
- 需要进一步研究验证该关联并探索其他人群中的风险。
研究设计与样本
- 系统文献检索获得14个与免疫相关不良事件相关的候选变异。
- 利用All of Us队列进行候选变异关联研究,建立ICI治疗队列(n=414)和一般队列(n=213,282)。
- 采用逻辑回归(校正性别)分别按自报种族和祖先估计种族评估各候选基因型的影响。
- 采用Kaplan-Meier生存分析评估遗传效应对无AKI生存的影响。
主要发现
- ICI队列(n=414)一年AKI发生率为23.2%,显著高于一般队列(6.5%,n=213,282)。
- 自报白人中rs16957301(chr13:100324308,T>C)与ICI-AKI风险显著相关(Beta=0.93,CI:0.32-1.54,OR=2.53,Bonferroni校正P=0.047)。
- 祖先估计欧洲人中rs16957301与ICI-AKI风险显著相关(Beta=0.94,CI:0.31-1.57,OR=2.56,Bonferroni校正P=0.044)。
- 自报白人携带rs16957301风险基因型(TC/CC)者AKI发生显著更早(3.6个月 vs 参考基因型TT 7.0个月,log-rank P=0.04),祖先估计欧洲人中结果一致。
- 该变异在一般队列中未呈现显著AKI风险(Beta:-0.008-0.035,FDR:0.75-0.99)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 需要进一步研究验证该关联并探索其他人群中的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Immune checkpoint inhibitors (ICIs) enhance the immune system's ability to target and destroy cancer cells, but can also trigger immune-related adverse events (irAEs), such as acute kidney injury (ICI-AKI), complicating patient management. Limited knowledge of genetic predispositions to ICI-AKI highlights the need for genomic studies to improve therapeutic strategies. OBJECTIVE: To identify genetic predispositions for ICI-AKI using large-scale real-world data. METHODS: A systematic literature search led to 14 candidate variants related to irAEs. We performed a candidate variant association study with these variants using the All of Us cohort. An ICI-treated cohort and a general cohort were established to evaluate ICI-AKI risk. Logistic regression, adjusted for sex, evaluated the impact of each candidate genotype, separately for self-reported and ancestry-estimated race. Kaplan-Meier survival analysis assessed genetic effects on AKI-free survival. RESULTS: The ICI cohort (n = 414) showed a one-year AKI incidence rate of 23.2 %, significantly higher than the general cohort (6.5 %, n = 213,282). The rs16957301 variant (chr13:100324308, T > C) in the PCCA gene was a significant risk genotype for ICI-AKI among self-reported White (Beta=0.93, CI: 0.32 - 1.54, ORs= 2.53, Bonferroni-corrected P-value=0.047) and ancestry estimated Europeans (Beta = 0.94, CI: 0.31 - 1.57, ORs= 2.56, Bonferroni-corrected P-value=0.044). Self-reported White with the rs16957301 risk genotypes (TC/CC) developed AKI significantly earlier (3.6 months) compared to the reference genotype (TT, 7.0 months, log-rank P = 0.04). Consistent results were found in ancestry-estimated Europeans. This variant did not present significant AKI risks in the general cohort (Beta: -0.008-0.035, FDR: 0.75-0.99). CONCLUSION: Our findings suggest that rs16957301 in PCCA may serve as an ICI-AKI risk marker in Caucasians. Further studies are needed to validate this association and explore risks in other populations.
引用
- Wang Y, Xiong C, Yu W, et al. PCCA variant rs16957301 is a novel AKI risk genotype-specific for patients who receive ICI treatment: Real-world evidence from all of us cohort. Eur J Cancer. 2024. PMID: 39536432. doi:10.1016/j.ejca.2024.115114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。